Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
solasonine
- Development stage
- Unknown
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Topical
01
Overview
Solasonine is a steroidal glycoalkaloid found in various Solanum species, including Solanum nigrum and S. linnaeanum. It is a glycoside of solasodine and exhibits cytotoxic properties, particularly at high concentrations, by disrupting cell membrane integrity and inducing apoptosis. Traditionally used in herbal medicine for its anti-inflammatory and antiviral effects, recent research highlights its anticancer potential through mechanisms such as induction of apoptosis, cell cycle arrest (via AMPK/FOXO3A pathway), activation of ferroptosis, inhibition of PI3K/AKT and ERK/MAPK signaling pathways, suppression of neuropilin-1 (NRP1), and modulation of microRNA expression (e.g., miR-486-5p). Clinically, it has been included as a component in the topical formulation Curaderm BEC5 for actinic keratosis and certain skin cancers. However, high doses are toxic to humans due to their ability to disrupt cellular membranes[2][5][6][7][8].
- Brand names
- Curaderm BEC5
- Other names
- solasonineSolasoninTomatine solaradixine
02
Targets
AcetylcholinesteraseMAPK3 (Mitogen-activated protein kinase 1)NRP1 (Neuropilin-1)MPTP (Mitochondrial permeability transition pore)AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)
Beyond the preview
Go deeper on solasonine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on solasonine.